US Patent

US10596155 — Aqueous-based metronidazole gel formulations

Formulation · Assigned to Chemo Research SL · Expires 2032-06-28 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects mucoadhesive aqueous-based gel formulations of metronidazole for intravaginal application to treat bacterial vaginosis.

USPTO Abstract

The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.

Drugs covered by this patent

Metro I.V. In Plastic Container (METRONIDAZOLE) · Baxter

Patent Metadata

Patent number: US10596155
Jurisdiction: US
Classification: Formulation
Expires: 2032-06-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Chemo Research SL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.